Braintale is a company focused on accelerating drug development and empowering precision neurology to improve brain care.

Braintale

Deciphering white matter to enable better care

Bpifrance

AGORANOV

Paris Business Angels

Femmes Business Angels

Angels Santé

Arts et Métiers Business Angels

BrainTale

Who's behind Braintale? For this summer episode, please meet Lisa Marcheval in charge of .... #communication! It's already been (almost!) two years since she joined us. Time flies... 

We'll be back in September for the continuation of the "Employee of the month" series! 🏖️

Braintale recherche à élargir son équipe Business ! 🤩

Thanks La Gazette du LABORATOIRE Diag & Santé! Another opportunity to discover BrainTale and our partnership with AP-HP, Assistance Publique - Hôpitaux de Paris Tiers lieu BOpEx. An example of key collaboration for Braintale, with the support of Nicolas Castoldi and Pierre-Yves Brossard.  

Ans also.. a great wink to the Little Prince! ⭐😉  

https://lnkd.in/e7ue2kPk

(Re)listen to Fanny Mochel, Coordinator of the Paris Rare disease center for Leukodystropies sharing the results of the recently published study in Brain and entitled “Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy” by our partner Minoryx Therapeutics. 

Thanks to its biomarker platform, BrainTale has been able to highlight the evolution of #myelin lesions in patients suffering from #adrenoleukodystrophy with its easily accessible and non-invasive approach as described in the peer-review publication 🧠🚀 

👇👇👇 
https://lnkd.in/efbZ-MzX

📣 First peer-review publication in the journal Brain unveiling the relevance of BrainTale’s biomarker platform to monitor disease evolution and demonstrate therapeutic efficacy for #cerebral adrenoleukodystrophy (CALD) patients. 
This article with Marianne Golse as first author confirms the benefits of white matter measures provided by BrainTale as non-invasive reliable and objective lesion-assessment tool during drug development targeting white matter diseases. 🚀🧠 

#leukodystrophy #whitematter #multiplesclerosis #biomarker 

👇 The article can be found in comments below 👇

🎉 Scientific symposium & family conference organized by the United Leukodystrophy Foundation ! 

During 3 days, scientists and experts of the field shared latest research work and studies on #Leukodystrophies to advance care for patients. 
A crucial work to improve quality of life for patients living with these diseases and their families. 

A big thank you to all the speakers, among other Marc Engelen, Eric Mallack, Arun Mistry, Florian Eichler for their talks and thank you to events sponsors such as Minoryx Therapeutics, Vigil Neuroscience and SwanBio Therapeutics. 

Our work at BrainTale is focused on helping you develop new drugs and improve care for patients with #demyelinating diseases and #neurodegenerative diseases. 

Let's continue !
https://lnkd.in/ezk9hQYR

Braintale presented during an oral communication its study on differential diagnosis of parkinsonian syndromes. Presented data highlight the sensitivity of white matter markers provided by BrainTale for enabling an efficient and robust classification of Parkinsonian syndromes. And more specifically, differentiating PD vs MSA and PSP, two frequent confusing syndromes. A first step with Stéphane Lehéricy and the team towards better Parkinson’s patients care.

Great discussions alongside this communication during the 10th European Academy of Neurology congress held in Helsinki for Vincent Perlbarg, co-founder and Scientific Director and Martin Grange, data scientist.  
Braintale is building step by step the value of its #brain #biomarkers for the management of #NeurodegenerativeDiseases such as #Parkinson's disease 🧠🚀 

Find out more about the study 👇👇

Today Florence Kocher, Braintale's CBO, and Marine Bourgeais, Brand Manager at Braintale, are attending the ULF (United Leukodystrophy Foundation) Annual Scientific Symposium, bringing together researchers and physicians whose recent research into #leukodystrophies is of major importance and critical for this high need patient population. 🧠 

It can only strengthen Braintale’s involvement in the #diagnosis and care of #adrenoleukodystrophy patients !

🔎 When a patient with #adrenoleukodystrophy is diagnosed with a progressive and inflammatory evolution of #demyelination. Patient’s life is at stake: death could occur within 2 to 4 years. 

There is no treatment available. The current standard of care is a hematopoietic stem cell transplantation (HSCT) to halt the #neuroinflammation. Yet, its efficacy is strongly related to the accuracy and timing of #diagnosis. Too often, patients are diagnosed at an advanced stage and are thus not eligible anymore for HSCT. In addition, HSCT does not seem to prevent the progression of degenerative myelopathy. 🧠

Therefore, there is a crucial need for relevant, sensitive and specific #biomarkers to monitor disease evolution, optimize #care with the right treatment at the right time, and support new disease-modifying therapies development for tomorrow. At BrainTale, we are committed to providing objective and reliable solutions to caregivers and drug developers to improve adrenoleukodystrophy patients care. 🤝🚀
 
Reference:  
https://lnkd.in/eUKgMaQM

BRAI

EU:BRAINTALE

Braintale